Lenacapavir is the first twice-daily injectable drug for the prevention of HIV infection, with 99.9% efficacy in clinical trials. Recommended by the CHMP, this treatment simplifies prevention by eliminating the need for daily tablets. In Romania, where the cost of HIV treatment is high, the new PrEP could reduce costs and improve access for vulnerable people. Approved at European level, this drug represents a significant opportunity to transform HIV prevention into public health policy.
Sources
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o şansă uriaşă pentru prevenţia HIV în România
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o șansă uriașă pentru prevenția HIV în România
Omenirea, mai aproape ca niciodată de a opri virusul HIV. Europa a autorizat tratamentul revoluționar
E.U. regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission
Latest News
18:13
A committee in the U.S. Senate voted to impeach Anthony Fauci after he refused to answer questions about the management of the COVID-19 pandemic.
18:10
Ilie Bolojan avoids a clear answer regarding the publication of his partner's wealth in the context of the Integrity Law
17:59
The National Museum of Romanian History has launched a page dedicated to the restoration of the helmet from Coșofeni, where the public can follow the stages of the conservation process.
17:50
The Russian Ministry of Foreign Affairs does not intend to recall its ambassador from Romania and threatens with "an appropriate response"
17:39
The first two barges in the Danube will be sunk on Thursday, and the other two on Friday, to ensure the operation of the Cernavodă power plant.
See more news